MLICM
BOLT icon

Metropolitan Life Insurance Company (MetLife)’s Bolt Biotherapeutics BOLT Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio BOLT Stock Details BOLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-360
Closed -$91K – 2788
2021
Q3 		$91K Buy
+360
New +$102K ﹤0.01% 2575
2021
Q2 		– Sell
-219
Closed -$144K – 2729
2021
Q1 		$144K Buy
+219
New +$143K ﹤0.01% 2235

Other funds holding BOLT

NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s BOLT Position: Q4 2021 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Bolt Biotherapeutics (BOLT) in Q4 2021, closing a stake of 360 shares — an estimated $91K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in BOLT in Q1 2021 and held it in 2 quarters. The position peaked at $144K in Q1 2021. 62 funds tracked by Wall St. Rank hold BOLT as of Q4 2021.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining Bolt Biotherapeutics position as of Q4 2021 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 360 Bolt Biotherapeutics shares in Q4 2021, an estimated $91K.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in Bolt Biotherapeutics in Q1 2021 and held it in 2 quarters.
  • Metropolitan Life Insurance Company (MetLife)'s Bolt Biotherapeutics position peaked at $144K in Q1 2021.
  • 62 funds tracked by Wall St. Rank held Bolt Biotherapeutics as of Q4 2021.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q4 2021, filed 15 Feb 2022.